Chronic Central Serous Chorioretinopathy
11
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
36%
4 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (11)
Steroid Eye Drops in Chronic Central Serous Chorioretinopathy
Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma
Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy
Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy
Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population
Pseudo-PDT in Central Serous Chorioretinopathy
Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate
A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)